Group 1 - The company held its 31st meeting of the 10th Board of Directors on August 20, 2025, with all 13 directors present, confirming the meeting's legality and effectiveness [1] - The company approved the 2025 semi-annual report and its summary, with a unanimous vote of 13 in favor [1] - The company conducted a risk assessment report on China National Pharmaceutical Group Finance Co., which was approved by the independent directors, with 8 votes in favor and 5 abstentions [2] Group 2 - The company decided to publicly sell idle assets, specifically a property located at 52 Jianshe Road, Chengdu, with the initial transfer price not lower than the assessed value [2] - The board authorized the management to handle the related matters for the public transfer of the property [2]